Patient population for bioequivalence study [Regulatives / Guidelines]

posted by DavidManteigas – Portugal, 2017-10-06 12:34 (2830 d 16:17 ago) – Posting: # 17866
Views: 3,941

It is hard to provide a valuable opinion without knowing much details, namely whether you're talking about a biosimilar or generic. :-D

Generally, the product-specific guideline states in which condition should be bioequivalence study be performed. For instance, in USA diclofenac is approved for 3 indications but for BE only a study in subjects with osteoarthritis of the knee is required (https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm244644.pdf). If no product-specific guideline exists, I would recommend you to ask for scientific advice on which patient population should be selected for the BE study with clinical endpoint. If I were the Sponsor, I would pick the condition on which the primary endpoint presents less variability in the outcome.

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,679 registered users;
34 visitors (0 registered, 34 guests [including 14 identified bots]).
Forum time: 04:51 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5